Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2024
0mins
Should l Buy ?
Source: Benzinga
- Virios Therapeutics, Inc. Public Offering: Virios Therapeutics, Inc. experienced a sharp decline in shares after pricing a $1.7 million public offering of 8.5 million shares at $0.20 per share.
- Stock Movements:
- MultiMetaVerse Holdings Limited MMV saw a 224% increase in shares due to an acquisition agreement.
- GT Biopharma, Inc. GTBP rose by 146% following better-than-expected quarterly results.
- Tantech Holdings Ltd TANH jumped by 89.8%.
- Faraday Future Intelligent Electric Inc. FFIE gained 62.1% ahead of its financial report.
- CN Energy Group. Inc. CNEY surged by 58%.
- Scorpius Holdings, Inc. SCPX increased by 57.8%.
- NKGen Biotech, Inc. NKGN rose by 46% after clearance for a Phase 2 trial.
- Bruush Oral Care Inc. BRSH jumped by 41%.
- Rekor Systems, Inc. REKR gained 36% post-partnership announcement.
- MIRA Pharmaceuticals, Inc. MIRA rose by 34.3%.
- Scilex Holding Company SCLX gained 34%.
- Hims & Hers Health, Inc. HIMS rose by 30.5%.
- BYND Cannasoft Enterprises Inc. BCAN surged by 29.5%.
- Cheetah Mobile Inc. CMCM gained 24.3%.
- Concord Medical Services Holdings Limited CCM jumped by 23%.
- Wix.com Ltd. WIX rose by 21.6%.
- Sintx Technologies, Inc. SINT shares rose by 21.1%.
- Sutro Biopharma, Inc. STRO climbed by 17.6%.
- PTC Therapeutics, Inc. PTCT jumped by 17.2%.
- Cue Health Inc. HLTH gained 17.1%.
- NextDecade Corporation NEXT climbed by 16%.
- NuScale Power Corporation SMR rose by 15.5%.
- VinFast Auto Ltd. VFS gained 15%.
- Crown ElectroKinetics Corp. CRKN shares rose by 14.8%.
- Tellurian Inc. TELL gained 14%.
- Shineco, Inc. SISI shares climbed by 10.2%.
- Independent Bank Group, Inc. IBTX gained 8.5%.
- Doximity, Inc. DOCS surged by 5.1%.
- Declines in Stock Prices:
- Akoustis Technologies, Inc. AKTS fell by 53.8%.
- Cheetah
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
